baber/WOPTO huggingface dataset:
Patent NZ-552370-A (NZ)
Title: System for providing powder coated reconstituted cellulosic substrate
Inventor: BRUCE ALEXANDER MARK
IPC: B05D1/04
Filed: 2004-07-27
Abstract: Disclosed is a process for preparing a powder coated reconstituted cellulosic substrate comprising: providing a reconstituted cellulosic substrate comprising cellulose based particles and a cured formaldehyde based resin, wherein an inorganic salt is dispersed throughout the substrate; applying a powder coating composition to at least one surface of said substrate; and curing the powder coating composition. Also disclosed is a powder coated reconstituted cellulosic substrate containing formaldehyde-based resin and an inorganic sulphate salt.
Patent NZ-564541-A (NZ)
Title: Macrocyclic inhibitors of hepatitis C virus
Inventor: RABOISSON PIERRE JEAN-MARIE BERNARD
IPC: A61K38/05
Filed: 2006-07-28
Abstract: Disclosed are macrocylic compounds of formula (I) having inhibitory activity on the replication of the hepatitis C virus (HCV), and the N-oxides, salts, and stereochemically isomeric forms thereof, wherein the variables are as defined in the specification; pharmaceutical compositions containing these compounds of formula (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
Patent NZ-565460-A (NZ)
Title: Nitrocatechol derivatives as COMT inhibitors
Inventor: LEARMONTH DAVID ALEXANDER
IPC: A61K31/421
Filed: 2006-07-26
Abstract: Disclosed is a ntirocatechol derivative of formula (I), where the variables and substituents are as defined in the specification. Also disclosed is the use of the compound to treat central and peripheral nervous system disorders, such as Parkinson's, parkinsonian disorders, gastrointestinal disorders, edema formation states, and hypertension.
Patent NZ-568435-A (NZ)
Title: Method and apparatus for processing of materials with bearings supporting rotating drum being sealed from heat and pressure added in interstitial space
Inventor: BOOTS GORDON C
IPC: A61L11/00
Filed: 2006-12-05
Abstract: A treatment vessel has a drum 200 to which pressure and heat can be applied and rotationally supported within a shell via roller 400. The drum is supported by bearings 440, 490 which are sealed from pressure and heat added to the interstitial space between the drum and the shell.
Patent NZ-569742-A (NZ)
Title: Method and apparatus for treating roots in and around a conduit using a microwave transmitter
Inventor: KRUMINS ANDRIS
IPC: A01M21/04
Filed: 2007-01-12
Abstract: Disclosed is a method of treating tree or plant roots (12) in and/or around a conduit (20), to kill or inhibit growth of the roots which can breach underground pipes. The method includes the steps of: positioning a microwave transmitter (1) within the conduit near the roots to be treated, and irradiating the roots with microwave radiation from the transmitter to kill or inhibit growth of at least a portion of the roots.
Patent NZ-571896-A (NZ)
Title: 1-Alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and use thereof
Inventor: DELUCA HECTOR F
IPC: A61P35/00
Filed: 2007-04-05
Abstract: Disclosed is a 1-Alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compound of formula (I) such as (20R)-1alpha-hydroxy-2-(3'-hydroxypropylidene)-19,24,25,26,27-penta-nor-vitamin D3; and (20R)-1á-hydroxy-2-(3'-hydroxypropylidene)-19,23,24-tri-nor-vitamin D3. Also disclosed is the method for making a compound of formula (I).
Patent NZ-572221-A (NZ)
Title: A self latching latch
Inventor: RYCROFT ALEXANDER NEAL
Filed: 2008-10-22
Abstract: A self latching latch mechanism is disclosed which includes a latch mounted to a first wing and a strike mounted to a second wing or a fixed member. The latch has a latch tongue which can move between a latching position in which the latch tongue can engage the strike to secure the first wing relative to the second wing or fixed member, and a free position which allows relative movement between the first wing and the second wing or fixed member. Latch tongue biasing means are provided to bias the latch tongue towards the latching position. Operating means are also provided to move the latch tongue from the latching position to the free position, and there is a hold back member which can move between a first position in which the latch tongue is prevented from moving to the latching position, and a second position in which the latch tongue can move to the latching position. The hold back member is biased to the first position. There is also a latch magnet associated with the hold back member, and means to prevent the latch tongue from moving from the latching position to the free position otherwise than upon operation of the latch tongue operating means. The strike also has a strike magnet. When the latch is close enough to the strike for the latch tongue to engage the strike the hold back member is caused to move from the first position to the second position by attractive or repulsive magnetic forces between the latch magnet and the strike magnet, thereby allowing the latch tongue to move from the free position to the latching position.
Patent NZ-574037-A (NZ)
Title: Indeno[1,3]oxazoles and indeno[1,3-thiazoles] and pharmaceutical use thereof
Inventor: UCHIKAWA OSAMU
IPC: A61K31/4184
Filed: 2007-06-18
Abstract: Disclosed are indeno[5,4-d][1,3]oxazol-8-ylidene acetamides represented by the depicted formula (I), wherein X is O or S and the remaining substituents are as defined in the specification, processes for their preparation and intermediates for use therein. The compound is useful for the prevention or treatment of sleep disorders and depression, bipolar disorder.
Patent NZ-581811-A (NZ)
Title: Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
Inventor: LY TAI WEI
IPC: A61K31/33
Filed: 2008-06-18
Abstract: Disclosed are particulates of { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)- benzyl)pyrimidin-5-yl} acetic acid, in crystalline Form I; wherein the crystalline Form I has a differential scanning calorimetric thermogram with an endotherm at a peak temperature of about 224 ºC and an onset temperature of about 220 ºC, wherein the differential scanning calorimetric thermogram is obtained at a heating rate of 10 ºC/min; and the particulates have an average particle size ranging from about 0.1 to about 150 mm; and wherein: the crystalline Form I has an X-ray powder diffraction pattern with one or more peaks expressed in two-theta at approximately 9.8, 13.1, 22.0, and 26.4º. Further disclosed is a process for the preparation of the particulates of { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid in crystalline Form I, comprising contacting { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)- pyrimidin-5-yl} acetic acid with a solvent such as acetonitrile, chloroform, dichloromethane, 1,4-dioxane, 2-methoxyethanol, MIBK, toluene, hexane(s), acetone, 1-butanol, DMSO, ethanol, ethyl acetate, ethyl formate, heptane, isobutyl acetate, 1-propanol, IPA, MEK, THF, water, and mixtures thereof.
Patent NZ-586610-A (NZ)
Title: Novel cytostatic 7-deazapurine nucleosides
Inventor: HOCEK MICHAL
IPC: C07H19/14
Filed: 2009-01-15
Abstract: Disclosed are cytostatic 7-deazapurine nucleoside compounds of formula (I), wherein the variables R1 is furanyl, thienyl, pyrrolyl, thiazoyl, imidazolyl, pyridyl, selenophenyl, or pyrazolyl and R2 is as defined in the specification, and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds. These compounds are suitable for inhibiting cell proliferation in tumour/cancer cells in a subject and can be used for treating a cellular proliferation disease, a neoplastic disease or cancer.
Patent NZ-593309-A (NZ)
Title: Wall proximity reclining chair with in-line linkage mechanism
Inventor: LAPOINTE LARRY P
IPC: A47C1/02
Filed: 2007-01-10
Abstract: A mechanism (32) to manually recline a chair in use and provide several adjustment means for a leg rest support is disclosed. The mechanism includes side plates (58, 60) with polymeric inserts (72, 73) and elongated slots (75, 75') to receive a pin (74, 74') to guide angle of rotation. Seat back support elements (62, 64) are coupled to the side plate and linked to the pin to allow rotation in unison. A rearward force applied by an occupant to the back support rotates them rearward with pins sliding within the elongated slots. When the rearward force is removed the occupant's weight returns the support elements to a pre-rotation position. Leg rest support arms (36, 37) are connected by a pantograph linkage set (34, 35) to a drive rod (78) positioned through the side plates. A cam (98) can be manually adjusted to support varied leg weights of occupants on the leg rest. A release latch or lever located on the side of the chair allows the user to position the leg rest between a stowed and extended position.
Patent NZ-596017-A (NZ)
Title: Ionophore antibiotic veterinary composition and method of manufacture
Inventor: MUNRO JOHN MORLEY
IPC: A61K31/35
Filed: 2011-10-26
Abstract: 596017 Disclosed herein is a water dispersible granule ionophore antibiotic composition, said composition comprising: from 5 to 80% w/w of at least one ionophore antibiotic; from 10 to 90% w/w of at least one filler-binder; from 0.1 to 20% w/w of at least one surfactant; from 0.1 to 20% w/w of at least one dispersing agent; and from 0.1 to 30% of at least one disintegrant; and a method of preparing said composition. Additionally disclosed is a method of prociding an ionophore antibiotic to a non-human animal, said method comprising directly or indirectly adding an effective amount of the water dispersible granule to the drinking water of said animal.
Patent NZ-597923-A (NZ)
Title: Protein glycosylation
Inventor: WREN BRENDAN
IPC: A61K39/02
Filed: 2010-09-03
Abstract: NZ 597923 Disclosed is a microbial cell transformed with a vector comprising a nucleotide sequence selected from the group consisting of a nucleic acid molecule consisting of a nucleic acid sequence as represented in Figure 1 a, as defined in the specification; a nucleic acid molecule consisting of a nucleic acid sequence that hybridises under stringent hybridisation conditions to the nucleic acid molecule in (i) and which encodes an polypeptide; wherein said cell expresses a recombinant polypeptide which is a substrate for said oligosaccharyltransferase polypeptide. Also disclosed is a vaccine composition comprising a bacterial glycoconjugate antigenic polypeptide, or part thereof, said polypeptide including at least one peptide motif consisting of the amino acid sequence: Asp/Glu-Xaa1-Asn-Xaa2-Ser/Thr, wherein Xaa1 and Xaa2 is any amino acid except proline and further wherein said motif is modified by a oligosaccharyltransferase polypeptide selected from the group consisting of: a nucleic acid molecule consisting of a nucleic acid sequence as represented in Figure 1 a, as defined in the specification; a nucleic acid molecule consisting of a nucleic acid sequence that hybridises under stringent hybridisation conditions to the nucleic acid molecule in (i) and which encodes an oligosaccharyltransferase polypeptide.
Patent NZ-600281-A (NZ)
Title: Compositions and methods for the treatment of infections and tumors
Inventor: SHARPE ARLENE
IPC: A61K39/00
Filed: 2007-12-26
Abstract: Use of activated T-cells and a PD-1 antagonist in the manufacture of a medicament for inducing an immune response to a tumour antigen of interest for treating said tumour, wherein the tumour is a melanoma. The PD-1 antagonist can be an anti-PD-1, anti-PD-L1 or anti-PD-L2 antibody or inhibitory antisense RNA to PD-1, PD-L1 or PD-L2.
Patent NZ-600816-A (NZ)
Title: Inhibitors of flaviviridae viruses
Inventor: CLARKE MICHAEL O’NEIL HANRAHAN
IPC: A61K31/381
Filed: 2011-01-14
Abstract: Disclosed are thiophene compounds of Formula (I): and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. Example of compounds of formula (I) is: 5-(3,3-dimethyl-but-1-ynyl)-3-{ { 4-transmethyl-cyclohexanecarbonyI)-[4-(tetrahydro-pyran-4-yloxycarbonylamino)cyclohexyl]-amino} -thiophene-2-carboxylic acid.
Patent NZ-602948-A (NZ)
Title: Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
Inventor: VAISBURG ARKADII
IPC: A61K31/4365
Filed: 2011-04-08
Abstract: Disclosed are thieno[3,2-b]pyridine derivatives selected from 3-[(6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl]-1-ethyl-3-[2-methoxyethyl]urea, N-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yI)methyl)-N-(2-methoxyethyl)formamide, N-((6-(7-(4-(3-cyclopropylureido)-2,3-difluorophenoxy)thieno[3,2-b]pyridin-2-yl)-pyridin-3-yl)methyl)-N-(2-methoxyethyl)acetamide, 1-cyclopropyI-3-(3-fluoro-4-(2-(5-((4-(2-hydroxyacetyl)piperazin-1-yl)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, (S)-2-(4-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)piperazin-1-yl)-2-oxoethyl 2-amino-3-methylbutanoate, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-((2-(methylsulfonyl)ethylamino)methyl)pyridin-2-yl)thieno[3,2-b ]pyridin-7-yloxy)phenyl)urea, 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-((2-hydroxyethyl)(methyl)amino)ethyl)-1H-pyrazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea, 1-((2-(7-(4-Isopropylaminocarbonylamino-2-fluorophenoxy)thieno[3,2-b ]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-3-isopropyl-1-(2-methoxyethyl)urea, N-((2-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)-1-methyl-1H-imidazol-5-yl)methyl)-2-hydroxy-N-(2-methoxyethyl)acetamide, 1-cyclopropyl-3-(3-fluoro-4-(2-(5-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea and 1-cyclopropyl-3-(3-fluoro-4-(2-(1-(2-morpholinoethyl)-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenyl)urea. Further disclosed is a composition comprising a compound as defined above and a pharmaceutically acceptable carrier, for treating an ophthalmic disease, condition or disorder, wherein the ophthalmic disease, disorder or condition is selected from the group consisting of (a) a disease, disorder or condition caused by choroidal angiogenesis (including age-related macular degeneration), (b) diabetic retinopathy and (c) retinal edema.
Patent NZ-603962-A (NZ)
Title: Heat pump system
Inventor: CAVILL JOHN PERCIVAL
IPC: F24D17/00
Filed: 2011-07-01
Abstract: Disclosed is a heat pump system (10) for raising a temperature of a load (16), such as a domestic water tank, to at least a desired temperature. A first working fluid circuit (12) is arranged to receive heat energy from an external heat energy source and then directly transfer some of its heat energy to the load to raise the temperature of the load to at least an intermediate temperature, if the temperature of the load is less than the intermediate temperature. An indoor second working fluid circuit (14) is arranged to directly receive some of the heat energy from the first working fluid circuit and then directly transfer some of its heat energy to the load to further raise the temperature of the load from the intermediate temperature to at least the desired temperature, if the temperature of the load is less than the desired temperature. A load circuit (16) circulates the load liquid to be heated. The load circuit includes a pump (21) to control the flow rate of the load liquid in the load circuit to assist with controlling the temperature of the load liquid in the load circuit. The first working fluid circuit (12) and the indoor second working fluid circuit (14) include respective controllable expansion valves (29, 32). A controller controls the controllable expansion valves (29, 32) and the pump (21) to optimise the system. An apparatus for use in a heat pump in a heat pump system for raising a temperature of a load positioned indoors is also provided.
Patent NZ-606294-A (NZ)
Title: B-cell reduction using cd37-specific and cd20-specific binding molecules
Inventor: JEFFREY A LEDBETTER
IPC: A61K39/395
Filed: 2006-07-25
Abstract: Disclosed is the use of one or more CD37-specific binding proteins in the manufacture of a composition for treating a disease or disorder associated with aberrant B cell activity, wherein the composition is to be administered in combination with rituximab.
Patent NZ-614891-A (NZ)
Title: Interrogatory cell-based assays and uses thereof
Inventor: NARAIN NIVEN RAJIN
IPC: G16B5/00
Filed: 2012-03-02
Abstract: Disclosed is method for identifying a modulator of a biological system, the method comprising: (1) establishing a model for the biological system using cells associated with the biological system to represent a characteristic aspect of the biological system; wherein the model of the biological system comprises cells associated with the biological system; (2) obtaining a first data set from the model for the biological system, wherein the first data set represents expression levels of a plurality of genes in the cells associated with the biological system; (3) obtaining a second data set from the model for the biological system, wherein the second data set represents a functional activity or a cellular response of the cells associated with the biological system; (4) generating a first causal relationship network model relating the expression levels of the plurality of genes and the functional activity or cellular response based solely on the first data set and the second data set using a programmed computing system, wherein the generation of the first causal relationship network model is not based on any known biological relationships other than the first data set and the second data set, and wherein the first causal relationship network model is based on a consensus network model produced by evolving an ensemble of trial networks; (5) generating a differential causal relationship network from the first causal relationship network model and a second causal relationship network model based on control cell data; and (6) identifying a causal relationship unique in the biological system from the generated differential causal relationship network, wherein a gene associated with the unique causal relationship is identified as a modulator of the biological system. Also disclosed is a method for identifying a modulator of a disease process.
Patent NZ-616558-A (NZ)
Title: New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
Inventor: GONZALEZ JOSE LORENZO
IPC: C07C291/00
Filed: 2013-10-11
Abstract: 616558 Disclosed is a Process for the synthesis of the compound of formula (I), 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, characterised in that the compound of formula (VIII), 3-(4,5-dimethoxyphenyl)propanenitrile is subjected to the action of N-bromosuccinimide in the presence of an organic solvent to yield the compound of formula (I). Compound of formula (I) is useful in the preparation of ivabradine, 3-{ 3-[{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl} (methyl)amino]propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one.
Patent NZ-619485-A (NZ)
Title: An animal shelter structure
Inventor: THOMAS GEORGE POW
IPC: E04H15/18
Filed: 2012-12-24
Abstract: An “outdoor” animal shelter structure with four sides, two opposite sides being major sides, includes a water impervious canopy (22) that is made of a material that is partially light transmissive and at least one side curtain (31). The canopy (22) is supported above at least part of a floor by side supports. The side curtain (31) at least partially covers at least one of the major sides and extends at least some way between the canopy (22) and the ground. The curtain (31) can be disposed so as to leave a gap (32) between the ground and the curtain (31) to allow air to flow below the curtain (31) and into space below the canopy and to leave a gap between the canopy and the top of the curtain to allow air to flow above the curtain and into the space below the canopy. The canopy is provided with a closable opening 39 to allow air to vent from the canopy.
Patent NZ-628305-A (NZ)
Title: Energy plant and parts of an energy plant
Inventor: SILTALA TIMO
IPC: H01F38/14
Filed: 2013-01-16
Abstract: The invention pertains to underwater energy plants utilizing water movement due to waves, tide or stream. The invention also relates to parts of such a plant, namely an underwater wing (9, 10, 11) for capturing wave energy, apparatus (12) to convert the mechanical energy to electrical energy, and a connector (46) for transferring the electrical energy. In certain embodiments of the invention, a wing (9, 10, 11) causes a moment around hinging axis due to water flow with autonomous or tethered in-hinge electric generator and underwater attachable high power electric connector (46) based on inductive transfer of energy. The wing (9, 10, 11) has a non-planar profile, and the profile form of the wing is asymmetric, and wherein the wing profile has two leading edges mirrored.
Patent NZ-705315-A (NZ)
Title: Tipping actuator for a conveyor system
Inventor: WHITE SHELDON PHILLIP
IPC: B65G47/94
Filed: 2012-09-06
Abstract: An armature for use in the grading of fruit is described. The armature provides smooth tilting of a fruit carrying cavity to mitigate damage to the fruit during discharge from the conveyor. The carriers (23) move along a conveyor (22) and through a ramp (19) to the armature (13a). The armature (13a) allows the carrier (23) to only tip partially (X) until the carrier moves past the armature, when it can tip fully (Y).
Patent NZ-715896-A (NZ)
Title: Humanized or chimeric cd3 antibodies
Inventor: PARREN PAUL
IPC: C07K16/28
Filed: 2014-07-04
Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment. In a particular embodiment the CD3 antibody comprises a binding region comprising heavy chain variable (VH) region as set forth in SEQ ID NO:6 and light chain variable (VL) region as set forth in SEQ ID NO:10 that has a reduced effector function or reduced T cell activation. In a further embodiment the CD3 antibody further comprises the deimmunizing mutations L234F, L235E, and D265A in a human IgG1 heavy chain and the amino acids in the positions corresponding to N297 and P331 are N and P, respectively.
Patent NZ-719078-A (NZ)
Title: Compositions and methods for modulating farnesoid x receptors
Inventor: CHIANELLI DONATELLA
IPC: C07D491/052
Filed: 2014-11-04
Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).